SLC18A2 and major depressive disorder: Recently, specific inhibitors of the vesicular monoamine transporter 2 (VMAT2) have been approved for the treatment of TD by the US Food and Drug Administration (FDA); however, according to a recent warning (4), the use of a VMAT2 inhibitor might cause depression and suicidal ideation by depleting the brain monoamines.